Form 4 for TAK TAKEDA PHARMACEUTICAL CO LTD
Accepted 2026-04-28 06:08:54 ET · period of report 2026-04-27 · accession 0001395064-26-000140 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2026-04-28 06:08 | 2026-04-27 | TAK | Weber Christophe Pierre | Pres, CEO, Dir | A - Grant | $0.00 | +244.3K | 418.8K | +140% | $0 |
| D | 2026-04-28 06:08 | 2026-04-27 | TAK | Weber Christophe Pierre | Pres, CEO, Dir | A - Grant | $0.00 | +79.0K | 125.3K | +170% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Ordinary Shares | 2026-04-27 | A | A | 78,900 | $0.00 | 1,014,200 | D | — | — | (F1) On July 1, 2023, the reporting person was granted an award of restricted stock units (RSUs), which vest in the form of ordinary shares based upon the achievement of the specified performance metrics, including core revenue, core operating profit, and important R&D milestones. On April 27, 2026 the Compensation Committee of the Board of Directors determined the number of RSUs to be awarded based on these performance metrics, which amount is reported above. (F2) Includes 174,900 restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one Ordinary Share. The RSUs vest on the following schedule: June 1, 2026 (125,000 shares), June 1, 2027 (32,700 shares) and June 1, 2028 (17,200 shares). |
| 2 | Common | American Depositary Shares | 2026-04-27 | A | A | 165,370 | $0.00 | 418,803 | D | — | — | (F3) On July 1, 2023, the reporting person was granted an award of restricted stock units (RSUs), which vest in the form of American Depositary Shares based upon the achievement of the specified performance metrics, including core revenue, core operating profit, and important R&D milestones. On April 27, 2026, the Compensation Committee of the Board of Directors determined the number of RSUs to be awarded based on these performance metrics, which amount is reported above. (F4) Includes 369,378 restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one American Depositary Share. The RSUs vest on the following schedule: July 1, 2026 (261,114 shares), July 1, 2027 (72,384 shares) and July 1, 2028 (35,850 shares). |
| 3 | Derivative | Tax Obligation Award | 2026-04-27 | A | A | 78,978 | $0.00 | 125,345 | D | — · 2026-06-01 to 2026-06-01 | 78,978 Ordinary Shares | (F5) Each Tax Obligation Award is the economic equivalent of one Ordinary Share that, upon vest, will be converted to a cash payment primarily to cover tax obligations at the then-current market price of the Ordinary Shares. |